Boston Scientific signed a definitive agreement to acquire Penumbra in a cash and stock transaction valued at approximately $14.5 billion on an enterprise value basis. The deal represents a strategic expansion of Boston Scientific’s cardiovascular franchise and establishes the company’s presence in mechanical thrombectomy and adjacent neurovascular markets. Penumbra shareholders will receive consideration valued at […]

The postBoston Scientific buys Penumbra in massive medtech dealappeared first onRolling Out.